Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033 - Projected to Generate Revenues of $20.63 Billion by 2028, Fueled by Advances in Liquid Biopsy and Personalized Medicine
December 13, 2024 09:49 ET
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Free DNA (cfDNA) Testing Market Outlook to 2028 & 2033" report has been added to ResearchAndMarkets.com's offering.The cell free DNA (cfDNA)...
Circulating Biomarkers and Extracellular Vesicles Europe 2024 - Two Day On Site Conference Takes Place in Rotterdam, Netherlands on June 24-25th 2024
June 06, 2024 07:42 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Circulating Biomarkers and Extracellular Vesicles Europe 2024" conference has been added to ResearchAndMarkets.com's offering.The Circulating...
Europe DNA/RNA Sample Extraction and Isolation Research Report 2024: A $1.23 Billion Market by 2033, Driven by Rising Demand for Genomic Analysis in Research, Diagnostics, and Forensic Applications
April 30, 2024 10:49 ET
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Europe DNA/RNA Sample Extraction and Isolation Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. ...
BIOCAPTIVA to conduct ex-vivo study to evaluate the potential of the BioCaptis device to capture cell free DNA to improve pleural disease diagnosis
October 12, 2023 03:00 ET
|
BIOCAPTIVA
Study aims to establish whether BioCaptis technology can be used to isolate cell free DNA (cfDNA) from pleural fluid samples in sufficient quantities for downstream DNA analysisGoal is to identify...
Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration
September 20, 2022 09:00 ET
|
Predicine
HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announced...
Predicine Expands to Europe with the recently launched CE-Marked cfDNA Assay PredicineCARE™ for Genomic Profiling in Blood and Urine
August 09, 2022 08:00 ET
|
Predicine
SILICON VALLEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company, has launched its CE-marked PredicineCARE™ for genomic profiling in blood and urine....
Circulating DNA/RNA Patent Landscape Report 2021: Oppositions and Litigations, Key Patent Analysis, Patent Database
July 05, 2021 06:53 ET
|
Research and Markets
Dublin, July 05, 2021 (GLOBE NEWSWIRE) -- The "Circulating DNA/RNA Patent Landscape 2021" report has been added to ResearchAndMarkets.com's offering. Circulating nucleic acids tests, an essential...
Precipio and PerkinElmer Collaborate to Provide Solutions for Liquid Biopsy Testing Workflows
November 01, 2018 09:15 ET
|
Precipio, Inc.
Precipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, Conn., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...
Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
May 15, 2018 09:52 ET
|
Exosome Diagnostics
Waltham, MA, May 15, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. received great interest from their presentations at the International Society for Extracellular Vesicles (ISEV) 2018 in...